Psychiatric disorders with electroconvulsive therapy (ECT) indication.
Conditions
Interventions
Intervention 1: Intervention group 1: The day before receiving ECT and after the Montreal cognitive test, rivastigmine is started at a dose of 1.5 mg in 24 hours and increases to 3 mg (2 capsules) in
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Being in the age range of 18-60 years. Being a candidate to receive electroconvulsive therapy. Collaborate to perform Montreal cognitive assessment. Having informed consent to participate in the study.
Exclusion criteria
Exclusion criteria: History of neurocognitive disorders such as delirium and dementia History of cardiac conductive disorder and arrhythmia History of hepatic, renal, thyroid, and seizure disorders History of sensitivity to rivastigmine and memantine History of electroconvulsive therapy within the the past 6 months Taking calcium channel blockers and cox-inhibitors
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cognitive impairment. Timepoint: One day before starting ECT, 2 and 6 weeks after starting ECT. Method of measurement: Montreal Cognitive Scale (MOCA). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactParniyan Molaee
Shahid Beheshti University of Medical Sciences
Outcome results
None listed